



Industry-Sponsored Symposia

PER

Saturday, March 4, 7:30 – 9:30 AM | Empire CD, 2nd Floor

The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients with Alzheimer Disease

Presented by Dr. Gary Small, Chair of the Department of Psychiatry at the Hackensack University Medical Center.

A variety of proteins related to various aspects of Alzheimer disease (AD) pathophysiology have been suggested as biomarkers for the condition. Cerebrospinal fluid biomarkers reflect the 3 well-established hallmarks of AD. This symposium will feature experts who will review state of the science on the role of new and emerging fluid biomarkers in AD.

PER Accreditation/Credit Designation

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

REGISTER NOW AT <https://www.gotoper.com/GPALZ23>



Eisai

Saturday, March 4, 7:00 – 9:00 PM | Empire CD, 2nd Floor

Defining Meaningful Benefits for Patients with Alzheimer's Disease: Timely diagnosis and interpreting treatment outcomes

Presented by Drs. Malaz Boustani and Sharon Cohen. Dr. Boustani is a Professor of Aging in the Research Division of General Internal Medicine and Geriatrics at Indiana University School of Medicine. Dr. Cohen is Medical Director and Site Principal Investigator at the Toronto Memory Program in Toronto, Canada. From this presentation attendees will

learn to identify the challenges related to early detection of Alzheimer's Disease (AD) faced by both patients and informal caregivers. Attendees will learn about the journey from primary care to memory care with a focus on what matters most to patients and caregivers. Hypothetical patient profiles will be presented to elucidate the diversity of patients with AD. Previous research and potential solutions to overcome challenges along the patient journey will be identified.



MedEdicus

Sunday, March 5, 7:00 – 9:00 AM | Empire CD, 2nd Floor

Person-Centered Care Approaches to the Treatment of Patients with Neuropsychiatric Manifestations of Parkinson's Disease

Presented by Dr. George T. Grossberg, the Samuel W. Fordyce Professor, Director, Geriatric Psychiatry in the Department of Psychiatry and Behavioral Neuroscience at the Saint Louis University School of Medicine; Dr. Danielle Larson, the Movement Disorders Specialist in the Ken and Ruth Davee Department of Neurology at Northwestern University Feinberg School of Medicine Chicago, Illinois; and Dr. Gary Small, Chair of Psychiatry at Hackensack University Medical Center in Hackensack, New Jersey. This educational activity is intended for psychiatric clinicians, including physicians, physician assistants, nurse practitioners, and nurses, caring for patients with Parkinson's disease. After completing this activity, participants will be better able to:

- Describe the use of behavioral management strategies to manage neuropsychiatric aspects of Parkinson's disease
- Develop evidence-based treatment strategies for patients with Parkinson's disease and comorbid neuropsychiatric conditions (eg, Parkinson's disease psychosis, Parkinson's disease dementia, depression, anxiety, and agitation)

This continuing medical education activity is provided by MedEdicus LLC in collaboration with Amedco LLC.

REGISTER NOW AT www.PDPCME.com



Neurocrine Biosciences

Monday, March 6, 7:30 – 9:30 AM | Empire CD, 2nd Floor

Recognition and Treatment of Tardive Dyskinesia With a Focus on Older Populations

Presented by Dr. Herbert A. Cruz, MD, Medical Director of Telepsychiatry at Kings View and Medical Director at Halcyon Behavioral Health in Fresno, California. Studies have demonstrated that older adults receiving antipsychotics have a greater risk for tardive dyskinesia (TD), even when treated with lower doses for a shorter duration. This program will provide a brief overview of TD, including impact, burden, and risk implications, with a focus on older patients and residents receiving psychotropic medications. Learn suggested practices through a review of guidelines on TD monitoring, an overview of the Abnormal Involuntary Movement Scale exam, and video clips from experts on how they adapt TD assessment for nonambulatory patients. Faculty will also present clinical data for an FDA-approved treatment option for adults with TD.

